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IL-33 promotes ST2-dependent lung fibrosis by the
induction of alternatively activated macrophages and
innate lymphoid cells in mice
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Charles McSharry, PhD,a and Damo Xu, PhDa,e Glasgow, United Kingdom, Nouzilly, France, Mecca and Jeddah, Saudi Arabia,
Baghdad, Iraq, and Beijing, ChinaBackground: The initiation and regulation of pulmonary
fibrosis are not well understood. IL-33, an important cytokine
for respiratory diseases, is overexpressed in the lungs of patients
with idiopathic pulmonary fibrosis.
Objectives: We aimed to determine the effects and mechanism
of IL-33 on the development and severity of pulmonary fibrosis
in murine bleomycin-induced fibrosis.
Methods: Lung fibrosis was induced by bleomycin in wild-type or
Il33r (St2)2/2 C57BL/6 mice treated with the recombinant
mature form of IL-33 or anti–IL-33 antibody or transferred with
type 2 innate lymphoid cells (ILC2s). The development and
severityof fibrosis was evaluated based on lung histology, collagen
levels, and lavage cytology. Cytokine and chemokine levels were
quantified by using quantitative PCR, ELISA, and cytometry.
Results: IL-33 is constitutively expressed in lung epithelial cells
but is induced in macrophages by bleomycin. Bleomycin
enhanced the production of the mature but reduced full-length
form of IL-33 in lung tissue. ST2 deficiency, anti–IL-33 antibody
treatment, or alveolar macrophage depletion attenuated and
exogenous IL-33 or adoptive transfer of ILC2s enhanced
bleomycin-induced lung inflammation and fibrosis. These
pathologic changes were accompanied, respectively, by reduced
or increased IL-33, IL-13, TGF-b1, and inflammatory chemokine
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1422macrophages to produce IL-13 and TGF-b1 and induced the
expansion of ILC2s to produce IL-13 in vitro and in vivo.
Conclusions: IL-33 is a novel profibrogenic cytokine that signals
through ST2 to promote the initiation and progression of
pulmonary fibrosis by recruiting and directing inflammatory
cell function and enhancing profibrogenic cytokine production
in an ST2- and macrophage-dependent manner. (J Allergy Clin
Immunol 2014;134:1422-32.)
Key words: IL-33, lung fibrosis, alternatively activated macro-
phages, type 2 innate lymphoid cells
Bleomycin is an important cancer chemotherapeutic agent.
However, its cytotoxic activity associated with DNA strand
cissation and reactive oxygen species induction can cause
severe side effects, including pulmonary fibrosis. This can be
recapitulated in experimental models designed to investigate the
pathogenesis of pulmonary fibrosis and some aspects of idiopathic
pulmonary fibrosis (IPF),1-3 a devastating treatment-refractory
interstitial lung disease of unknown origin.4,5 A better understand-
ing of the fibrotic process might lead to novel therapeutic
approaches for this unmet clinical need. Bleomycin-induced
fibrosis in susceptible C57BL/6 mice provides a reliable model
to study the underlying mechanisms of fibrosis.1
Although the pathogenic mechanisms of bleomycin-induced
fibrosis and IPF are not fully understood, both conditions are
characterized by alveolar epithelial injury, accumulation of
fibroblasts and myofibroblasts, and deposition of collagenous
extracellular matrix in the lung, which together compromise
functional gas exchange.1,2,4,5 Lung histology and bronchoalveolar
lavage (BAL) show inflammatory cytology, including neutrophils,
lymphocytes, and macrophages, which are thought to contribute
to fibrogenesis.1,2,4,5 Macrophages can be polarized into 2 pheno-
types: classically activated macrophages (M1 macrophages),
which are activated by IFN-g and LPS, or alternatively activated
macrophages (M2 macrophages), which are activated by IL-4
and IL-13.6,7 M1 macrophages express inducible nitric oxide syn-
thase and proinflammatory cytokines and protect against infection,
whereas M2 macrophages express arginase 1 and TGF-b1 and are
critically involved in tissue repair and fibrosis.6,7
The profibrogenic cytokines TGF-b1 and IL-13 are essential
for the development of lung fibrosis by promoting myofibroblast
differentiation and stimulating production of extracellular matrix
proteins, primarily collagen,4,5 and thus are important potential
therapeutic targets in fibrosis. Similar strategies can be applied
to other mediators, including cytokines of the IL-1 family, among
which IL-1 and IL-18 have a role in clinical and experimental
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IL-33 is a dual-function cytokine: the full-length IL-33
(flIL-33) form serves as an intracellular gene regulator in the
nucleus, and the mature IL-33 (mIL-33) form serves as an
extracellular cytokine after releasewhen cells sense inflammatory
signals or undergo necrosis.10-15 Once released, flIL-33 can be
processed by neutrophil-derived proteases into mIL-33.13
Although both flIL-33 and mIL-33 are able to bind to and signal
through their receptor, ST2, mIL-33 has a 10-fold higher affinity
and bioactivity than flIL-33.13 ST2 is expressed on most innate
cells, including macrophages and the newly identified type 2
innate lymphoid cells (ILC2s), and IL-33 plays a direct role in
the function of these cells.16-19 mIL-33 mainly elicits a type 2
immune response and is closely associated with allergic and
parasitic diseases.11,18-22 It has recently been reported
that nuclear flIL-33 potentiates bleomycin-induced lung
injury in an undefined but ST2-independent manner.9 The
expression of IL-33 mRNA is increased in IPF lung tissue9;
however, the role of mIL-33 as a cytokine in the fibrotic process
is unknown.
We have investigated the effect and mechanism of mIL-33 in
the initiation and exacerbation of bleomycin-induced fibrosis in
mice. We report here that mIL-33, through ST2, strongly
enhances bleomycin-induced pulmonary fibrosis, mainly by
promoting inflammatory cell infiltration and function, including
polarization of M2 macrophages and ILC2s, and enhancing their
IL-13 and TGF-b1 production.METHODS
Experimental details are provided in the Methods section in this article’s
Online Repository at www.jacionline.org.RESULTS
Bleomycin-induced fibrosis is impaired in
St22/2 mice
Groups of wild-type (WT) and St22/2 C57BL/6 mice were
given bleomycin or PBS intranasally on day 0. The mice were
killed on day 7 or 14 to investigate the role of the cytokineIL-33 in the development of bleomycin-induced fibrosis. WT
mice that received bleomycin had progressive lung inflammation
(Fig 1, A) and fibrosis (Fig 1, B) from day 7 compared with PBS
control mice. This bleomycin-induced inflammatory and fibrotic
response was demonstrated by enhanced inflammatory cell
infiltration and collagen deposition in the lung and quantified by
using histologic inflammatory and fibrosis scores (Fig 1, C).
The pathologic changes observed in WT mice given bleomycin
were significantly reduced in St22/2 mice given bleomycin
(Fig 1, A-C).
Compared with bleomycin-treated WT mice, bleomycin-
treated St22/2 mice also had significantly reduced infiltration
of neutrophils on day 7 and total leukocytes, including
macrophages, neutrophils, and lymphocytes, on day 14 in BAL
fluid (Fig 1, D). Furthermore, bleomycin-enhanced concentra-
tions of soluble collagen and the expression of collagen 3,
which is associated with early-repair fibrosis, were reduced in
St22/2 compared with WT mice (Fig 1, E and F), whereas
the expression of collagen 1 remained unchanged (data not
shown). Moreover, bleomycin-treated St22/2 mice have
reduced concentrations of IL-33, IL-1, and chemokines
(CXCL1, CXCL2 and CCL2) in lung tissue extracts
compared with concentrations seen in bleomycin-treated WT
mice (see Fig E1, A, in this article’s Online Repository at www.
jacionline.org).Neutralizing anti–IL-33 antibody attenuates
bleomycin-induced fibrosis
We next assessed the role of endogenous IL-33 in the
development of bleomycin-induced fibrosis by treating WT
mice with anti–IL-33 antibody. C57BL/6 mice were injected
intraperitoneally with anti–IL-33 every fifth day from day 0 of
bleomycin administration and killed on day 14. Anti–IL-33
antibody reduced IL-33 and IL-1 levels in the lung tissue of
bleomycin-treated mice compared with that seen in control
IgG-treated mice (see Fig E1, B). The antibody treatment also
markedly reduced bleomycin-induced airway inflammation
and lung fibrosis (Fig 2, A-C) and the number of macrophages,
neutrophils, and lymphocytes in BAL fluid on day 14 compared
with IgG control values (Fig 2, D). Furthermore, the antibody
treatment significantly reduced lung tissue soluble collagen
(Fig 2, E) and collagen 3 mRNA expression (Fig 2, F).Recombinant mIL-33 exacerbates bleomycin-
induced fibrosis in mice
Mice were administered intranasal mIL-33 together with
bleomycin on day 0 and lung tissues were analyzed on day 7 to
directly assess the role of the cytokine IL-33. Control mice
were given either PBS, mIL-33, or bleomycin alone. One
administration of exogenous mIL-33 significantly enhanced
bleomycin-induced lung inflammation (Fig 3, A), collagen
deposition (Fig 3, B), and pathology score (Fig 3, C), compared
with controls. The IL-33–enhanced histologic changes were
accompanied by significantly increased total numbers of cells in
BAL fluid, mainly neutrophils and lymphocytes, compared with
control values (Fig 3, D). The coadministration of IL-33 did not
change the macrophage numbers in BAL fluid at this time point
(7 days) compared with bleomycin alone. IL-33 further increased
the levels of bleomycin-induced collagen production (Fig 3, E)
FIG 1. St22/2mice have attenuated bleomycin (BLM)–induced fibrosis. Lung
hematoxylinandeosinstaining (A), collagenstaining (B), lungpathologyscore
(C), total anddifferential lung lavagecytology (D), lung tissue collagen content
(E), and lung tissue collagen3mRNAexpression (F)are shown.Vertical bars5
SEMs (n 5 5-7 mice per group per experiment). *P < .05 compared with PBS
control and #P < .05 compared with WT values. Data are representative of
3 experiments. Lym, Lymphocytes;Mac, macrophages;Neu, neutrophils.
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observed in control groups given one dose of IL-33 compared
with the PBS control.Bleomycin induces IL-33 production, which
promotes lung fibrosis through alveolar
macrophages
We next determined the kinetics of bleomycin-induced IL-33
expression in the lung. Mice were given bleomycin as above.
Bleomycin administration rapidly enhanced Il33 expression in
lung tissue from day 1 after bleomycin inoculation and lasted
for at least 14 days (Fig 4, A). Compared with PBS, bleomycin
treatment also enhanced lung tissue IL-33 protein production
(see Fig E2, A, in this article’s Online Repository at www.
jacionline.org) and St2 mRNA expression (see Fig E2, B).
Furthermore, although PBS control WT mice expressed only
flIL-33, bleomycin-treated WT mice markedly enhanced
mIL-33 concomitant with reduced flIL-33 production (Fig 4,
B). Bleomycin also increased production of neutrophil cathepsin
G (Fig 4, B) and myeloperoxidase in lung tissue compared with
that seen in PBS control in WT mice (see Fig E2, C). The
induction of IL-33 isoforms, cathepsin G, and myeloperoxidase
in St22/2mice given bleomycin was markedly reduced compared
with that seen in WT mice given bleomycin (see Fig E2, C-E).
Immunohistochemical analysis of lung tissue sections
of PBS- and bleomycin-treated WT mice demonstrated
that alveolar epithelial cells constitutively expressed IL-33
(Fig 4, C). However, administration of bleomycin induced
immunohistochemistry-detectable IL-33 protein in cells located
within the alveoli compared that seen in with PBS control mice
(Fig 4, C). The location and morphologic appearance of these
cells suggest that they are alveolar macrophages. The likelihood
that these cells were alveolar macrophages is supported by
fluorescence-activated cell sorting analysis, showing that
bleomycin treatment significantly increased the frequency and
number of IL-33–expressing F4/801 macrophages in the lung
(approximately 2.5 times the number seen in PBS control
mice). This increase was not seen in the St22/2 mice given
PBS or bleomycin (Fig 4, D).
We next evaluated the importance of alveolar macrophages in
bleomycin-induced and IL-33 plus bleomycin–exacerbated
lung fibrosis based on their depletion.19,23 Mice were treated
with clodronate in liposomes or control liposomes alone
administered intranasally on days 2 and 1 before administration
of bleomycin or bleomycin plus IL-33. This route of liposome
administration depletes alveolar but not lung parenchymal
macrophages.24 Clodronate depleted approximately 80% of
alveolar macrophages compared with the control group (Fig 4,
F) and significantly reduced bleomycin-induced and bleomycin
plus IL-33–exacerbated lung fibrosis (Fig 4, E) and inflammation
(see Fig E3 in this article’s Online Repository at www.jacionline.
org). Consistent with these observations, macrophage depletion
also reduced bleomycin-induced and bleomycin plus IL-33–
enhanced neutrophil and lymphocyte numbers in BAL fluid
(Fig 4, F) and collagen production in lung tissue (Fig 4, G)
compared with values seen in the control group given PBS.IL-33 polarizes M2 macrophages in lung fibrosis
M2 macrophages play a critical role in fibrogenesis.6 We have
shown previously that IL-33, together with IL-13, can polarize
alveolar M2 macrophages, but not M1 macrophages, in murine
allergic lung remodeling.19 Therefore we further investigated
the effect of bleomycin and IL-33/ST2 signaling on the
generation of M2 macrophages in patients with lung fibrosis.
FIG 2. Anti–IL-33 antibody treatment attenuates bleomycin (BLM)–induced fibrosis. Lung hematoxylin and
eosin staining (A), collagen staining (B), lung pathology score (C), total and differential lung lavage cytology
(D), lung tissue collagen content (E), and lung tissue collagen 3 mRNA expression (F) are shown. Vertical
bars 5 SEMs (n 5 5 mice per group per experiment). *P < .05 compared with PBS and #P < .05 compared
with IgG values. Data are representative of 3 experiments. Lym, Lymphocytes; Mac, macrophages; Neu,
neutrophils.
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80high) in the lung tissue of bleomycin-treated St22/2 mice was
slightly but significantly reduced compared with that of the
bleomycin-treated WT mice (Fig 5, A, and see Fig E4, A and B,
in this article’s Online Repository at www.jacionline.org).
Bleomycin markedly enhanced the number and percentage of
M2 macrophages (CD11b1F4/801CD2061) in the lungs of
WT, but not St22/2, mice on day 7 after bleomycin treatment
(Fig 5, B, and see Fig E4, C). Furthermore, bleomycin also
increased IL-331 M2 macrophage numbers (Fig 5, C, and seeFig E4, D and E) and expression of the gene encoding the M2
macrophage marker arginase 1 (Arg1), but not the M1
macrophage marker inducible nitric oxide synthase 2 (Nos2), in
lung tissue in WT mice compared with that seen after control
PBS treatment (Fig 5, D). The effects of bleomycin administra-
tion on macrophage polarization in St22/2mice given bleomycin
showed no increase in Arg1 expression and increased Nos2
expression compared with that seen in St22/2 mice given the
PBS control (Fig 5, C and D). However, the expression levels of
MHC class II, a common marker on all macrophages, in mice
FIG 3. Recombinant IL-33 exacerbates bleomycin (BLM)–induced fibrosis in mice. Mice were treated with
PBS, IL-33, and bleomycin with or without IL-33. Lung hematoxylin and eosin staining (A), collagen staining
(B), lung pathology score (C), total and differential lung lavage cytology (D), lung tissue collagen content
(E), and lung tissue collagen 3 mRNA expression (F) are shown. Vertical bars5 SEMs (n5 5 mice per group
per experiment). *P < .05 compared with PBS and #P < .05 compared with bleomycin values. Data are
representative of 3 experiments. Lym, Lymphocytes; Mac, macrophages; Neu, neutrophils.
J ALLERGY CLIN IMMUNOL
DECEMBER 2014
1426 LI ET ALgiven bleomycin were not significantly affected by St2 deficiency
compared with that seen in WT control mice (see Fig E4, F).
We further assessed the ability of bleomycin, IL-13, and IL-33
to polarizeM1 orM2macrophages in vitro. Mouse bone marrow–
derived macrophages (BMDMs) were cultured with medium or
bleomycin, IL-13, or IL-33 (alone or together), and the induction
of Arg1 and Nos2 was determined by using quantitative PCR
(qPCR). IL-13, but not IL-33, alone significantly induced Arg1,
but not Nos2, expression in macrophages compared with medium
control (Fig 5, E). The IL-13–induced Arg1 expression was
significantly increased by the presence of IL-33. However,
bleomycin alone or in combination with IL-13 or IL-33 had no
additional effect on the polarization of M1 or M2 macrophages
(Fig 5, E).Bleomycin and IL-33 induce fibrogenic cytokine and
chemokine production
IL-13 and TGF-b1 are key cytokines required for the
development of fibrosis.4,5,25 We next determined how theIL-33/ST2 pathway contributes to bleomycin-induced fibrosis
by assessing the cytokine and chemokine profiles induced by
bleomycin and IL-33. We first analyzed Il33, Il13, and Tgfb1
mRNA expression in the lung tissue of WTor St22/2 mice given
bleomycin with or without IL-33. Bleomycin significantly
induced expression of these cytokines in WT mice (Fig 6, A).
Consistent with the attenuated lung fibrosis seen in St22/2 mice
given bleomycin compared with that seen in WT mice given
bleomycin (Fig 1, A), bleomycin did not induce Il33, Il13, and
Tgfb1 expression in the lungs of St22/2 mice beyond that seen
in PBS-treated St22/2 mice (Fig 6, A). Furthermore, alveolar
macrophage depletion, which abolished bleomycin-induced and
IL-33–exacerbated lung fibrosis (Fig 4, E), also abrogated the
bleomycin and bleomycin plus IL-33–induced expression of
these cytokines (Fig 6, B).
We then determined the levels of key inflammatory cytokines
and chemokines in the BAL fluid of bleomycin-treated mice by
using Luminex (Luminex; Biosource, Invitrogen, Carlsbad, Calif)
or ELISA (BD Biosciences, San Jose, Calif). Only the fibrogenic
cytokines IL-1, IL-33, IL-13, and TGF-b1 and 3 chemokines
FIG 4. Bleomycin (BLM) induces IL-33 and IL-33 production and promotes lung fibrosis through alveolar
macrophages. WT and St22/2 mice were given bleomycin, and lung tissues were analyzed on day 7. A-D,
Il33mRNA expression (Fig 4, A); IL-33 isoforms, cathepsin G, and b-actin detected by using western blotting
(Fig 4, B); immunohistochemical staining of IL-33 (3400 magnification; Fig 4, C), and percentage and
number of IL-331 macrophages determined by using fluorescence-activated cell sorting (Fig 4, D). E-G,
Mice were given PBS, bleomycin, or bleomycin plus IL-33 and treated with clodronate or control liposomes.
Lung collagen staining and pathology score (Fig 4, E), total and differential lung lavage cytology (Fig 4, F),
and lung collagen content (Fig 4,G) are shown. Vertical bars5 SEMs (n5 6 mice per group per experiment)
*P < .05 compared with PBS and #P < .05 compared with bleomycin values. Data are representative of
2 experiments. Lym, Lymphocytes; Mac, macrophages; Neu, neutrophils.
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FIG 5. IL-33 polarizes M2macrophages. A-C,Numbers of macrophages (Fig 5, A), CD2061M2macrophages
(Fig 5, B), and IL-331 M2 macrophages (Fig 5, C). D, Lung tissue Arg1 and Nos2 mRNA expression.
E, BMDMs were stimulated with IL-13, IL-33, and bleomycin (BLM; alone or together). Arg1 and Nos2
mRNA expression was quantified. Vertical bars 5 SEMs (n 5 5 mice per group per experiment). *P < .05
compared with PBS and #P < .05 compared with WT values. Data are pooled from 3 experiments.
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bleomycin and bleomycin plus IL-33 (Fig 6, C, and see Fig E1).
No other type 2 and inflammatory cytokines were detected at
significant levels (data not shown). We also determined the levels
of key fibrogenic cytokines in BAL fluid. Bleomycin induced
IL-13 production from day 2, and IL-33 plus bleomycin induced
IL-13 synthesis from day 1; both returned to baseline by day 5
(Fig 6, C). Bleomycin-induced TGF-b1 production appearedfrom day 3 and increased progressively up to at least day 14
(Fig 6, C), and this was further increased by IL-33.
We further confirmed the ability of macrophages to produce
IL-13 and TGF-b1 in response to IL-33. BMDMswere stimulated
with IL-13, IL-33, or IL-13 plus IL-33. IL-33 stimulated BMDMs
to produce a significant amount of IL-13 compared with medium
alone (Fig 6, D). IL-13 or IL-33 alone stimulated significantly
increased levels of TGF-b1 compared with medium alone.
FIG 6. Bleomycin (BLM) and IL-33 induce fibrogenic cytokine production. A, Cytokine mRNA expression in
the lungs. B, Cytokine mRNA expression in the lungs of clodronate- or liposome-treated mice. C, IL-13 and
TGF-b1 production in lung lavage fluid. D and E, IL-13 and TGF-b1 in culture supernatants of BMDMs. F, Il13
mRNA expression in BMDMs. Vertical bars 5 SEMs (n 5 5 mice per group per experiment). *P < .05 and
#P < .05 compared with control values. Data are representative of 3 experiments.
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levels of TGF-b1 production (Fig 6, E) and Il13 expression in
macrophages (Fig 6, F).
IL-33 enhances ILC2 expansion and function in
fibrosis through ST2
Recent reports show that ILC2s are a major source of IL-13
in vivo and that IL-33 is a key inducer of ILC2s throughST2.17,26,27 We sought determine whether ILC2s also contribute
to the bleomycin plus IL-33–induced IL-13 production and lung
fibrosis. WT and St22/2 mice were given bleomycin or PBS
control, and the lineage-negative, inducible costimulator,
(ICOS)–positive ST21 ILC2s in the lungs were analyzed 3 to 7
days after bleomycin treatment (see Fig E5, A and B, in this
article’s Online Repository at www.jacionline.org).28 Bleomycin
treatment markedly enhanced ILC2 numbers in the lungs of WT
FIG 7. Induction and function of ILC2s in the lungs.A and B, Total number of ILC2s (Fig 7,A) and IL-131 ILC2s
(Fig 7, B). C-F, ILC2s were adoptively transferred into mice after bleomycin (BLM) instillation. Collagen
staining (Fig 7, C), pathology score (Fig 7, D), total/differential lung lavage cytology (Fig 7, E), and collagen
content (Fig 7, F) are shown. G and H, Collagen 3 (Fig 7, G) and Il13 and Tgfb (Fig 7, H) mRNA expression.
Vertical bars 5 SEMs (n 5 6 mice per group per experiment). *P < .05 compared with PBS and #P < .05
compared with bleomycin values. Data are representative of 2 experiments.
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(Fig 7, A). In contrast, ILC2s were almost completely absent in
St22/2 mice, irrespective of whether they were treated with
bleomycin. By day 7, the number of IL-131 ILC2s was enhanced
8-fold in WT mice given bleomycin compared with that seen in
PBS control mice (Fig 7, B, and see Fig E5, C). Again, IL-131
ILC2s were almost completely absent in St22/2 mice (Fig 7,
B). To understand the role of ILC2s in IL-33– and bleomycin-
induced pulmonary fibrosis, we adoptively transferred purified
ILC2s into WT mice 1 day after bleomycin and compared this
with conditions after bleomycin alone. The ILC2 transfer led to
exacerbation of lung inflammation and fibrosis compared with
bleomycin alone (Fig 7, C and D, and see Fig E5, D), and
this was similar to that observed after bleomycin plus IL-33
instillation (Fig 3). The pathogenic changes were accompanied
by increased inflammatory cell infiltration and collagen
production and expression of collagen 3, Il13, and Tgfb1 in
lung tissue compared with that seen in mice given bleomycin
alone (Fig 7, E-H, and see Fig E5, E).DISCUSSION
Data reported in this study reveal a hitherto unrecognized effect
and mechanism by which IL-33 exacerbates bleomycin-induced
lung fibrosis in mice (see Fig E6 in this article’s Online
Repository at www.jacionline.org). Bleomycin can elicit early
neutrophil infiltration and release of flIL-33 mainly by airway
epithelial cells and alveolar macrophages (see Fig E7 in this
article’s Online Repository at www.jacionline.org). flIL-33 can
then be processed into mIL-33 by neutrophil proteases, which
subsequently stimulates macrophages and ILC2s to produce
IL-13. IL-13 and mIL-33 then synergistically induce the
polarization of M2 macrophages and increase production of
IL-13 and TGF-b1. These cytokines are powerful activators of
fibroblasts, stimulating proliferation and increased collagen
synthesis and thereby amplifying pulmonary fibrosis. Thus
the IL-33/macrophage/M2 macrophage pathway is centrally
involved in the bleomycin-mediated fibrotic process, whereas
the IL-33/ILC2 pathway only contributes to the process by
providing a proportion of the IL-13 pool in fibrotic tissue
(see Fig E6).
Although a single administration of exogenous mIL-33 on its
own was not sufficient to induce pulmonary fibrosis by day 14
(Fig 3), we found that Il33 transgenic mice that constitutively
express low mIL-33 levels (approximately 80 pg/mL in serum)
spontaneously had lung interstitial fibrosis (see Fig E8 in this
article’s Online Repository at www.jacionline.org). Thus
mIL-33 is likely a key profibrotic factor.
We also show that the profibrogenic effect of mIL-33 is
mainly attributed to its role in M2 macrophage polarization.
Macrophages are polarized toward an M2 phenotype in a TH2
cytokine–dominant milieu,6 and local mIL-33, together with
IL-13, enhanced M2 macrophage polarization in our study.
Furthermore, the specificity of the requirement for IL-33 in this
process is demonstrated by the fact that bleomycin alone, which
was not able to induce M2 macrophage polarization in St22/2
mice, also did not cause fibrosis in St22/2 mice. We found that
macrophages are the predominant cells that express both IL-33
and ST2 in fibrotic lungs (see Figs E7 and E9 in this article’s
Online Repository at www.jacionline.org). Thus IL-33/ST2
signaling might promote M2 macrophage development andfunction in bleomycin-induced fibrogenesis in an autocrine and
paracrine fashion.
The profibrogenic cytokines TGF-b1 and IL-13 are necessary
for the development of tissue fibrosis.4,5,25 However, how
these cytokines are induced in bleomycin-induced fibrosis is
unresolved. Here we show that IL-33 signaling through ST2 is
essential for optimal induction of both IL-13 and TGF-b1
expression in bleomycin-induced lung fibrosis, although in
different cells. IL-33 primarily induces the production of IL-13
by both macrophages and ILC2s and production of TGF-b1 by
macrophages. These findings also suggest that mIL-33 is a novel
TGF-b1 inducer, which might explain its fibrogenic role in
bleomycin-induced fibrosis.
We demonstrated that bleomycin instillation increased the
infiltration of leukocytes, mainly neutrophils but also macro-
phages and lymphocytes, into the airways and lung interstitium.
This might be a consequence of IL-33/ST2–dependent and
independent production of the key chemokines CXCL1 and
CXCL2 in the context. As reported, CXCL1 and CXCL2
determine the migration of neutrophils, and CCL2 is used for
the migration of lymphocyte and monocyte/macrophage into the
inflamed lung tissue of mice.29,30 Because these chemokines are
mainly produced by macrophages,29,30 this might explain why
macrophage depletion also reduced lung lavage neutrophils and
lymphocytes in the setting of bleomycin-induced fibrosis.
The precise role of neutrophils in IL-33–exacerbated
pulmonary fibrosis is incompletely understood. We suggest an
additional role through which neutrophil proteases contribute to
fibrosis. We found that bleomycin simultaneously enhanced
the production of mIL-33 but reduced the production of flIL-33
in lung tissue. mIL-33 production was associated with
neutrophil cathepsin G production in the same lung tissue,
suggesting that flIL-33 was processed to mIL-33, which has
greater bioactivity.31 Because epithelial cells and alveolar
macrophages can produce CXCL1 and CXCL2 independent of
IL-33/ST2 signals,29,30,32 these cells might be responsible for
the bleomycin-induced early neutrophil infiltration in lung tissue
(see Fig E6).
A recent report showed that adenovirus-delivered flIL-33, the
form of IL-33 located in the nucleus, promoted lung fibrosis
through an undefined but ST2-independent mechanism.9 This
study, together with data in the present report, suggests that
both flIL-33 andmIL-33 are fibrogenic and that theymight induce
fibrosis through distinct mechanisms. These findings are themat-
ically linked with the data presented here; however, there are
several important differences between these 2 studies that might
together provide deeper understanding of the role of IL-33 in
fibrosis. We tested the role of mIL-33 as a secreted cytokine,
which acts through the cell-surface IL-33 receptor (ST2), whereas
Luzina et al9 tested the function of intranuclear flIL-33 delivered
through a viral vector. We used St22/2 mice of the fibrosis-
sensitive C57BL/6 strain, whereas Luzina et al9 used St22/2
mice of the fibrosis-resistant BALB/c strain.33 Thus the apparent
discrepancies between the 2 studies might be partly due to the
different mode of action of mIL-33 versus flIL-33 and the strain
of mouse used.
IL-33 is clearly detected in patients with several chronic
fibrotic diseases, including IPF, cystic fibrosis, and systemic
sclerosis.9,34,35 Given that inflammation and fibrogenesis are the
common pathogenic characteristic of these disorders and can be
exacerbated by IL-33, IL-33 might have a general contribution
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1432 LI ET ALto a range of fibrotic diseases. Therefore regulation of IL-33 could
be a novel therapeutic strategy for these diseases.
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Key messages
d Bleomycin enhanced the production of mIL-33 but
reduced flIL-33 production in lung tissue in vivo.
d ST2 deficiency, anti–IL-33 antibody, or alveolar macro-
phage depletion attenuated and exogenous mIL-33 or
adoptive transfer of ILC2s enhanced bleomycin-induced
lung fibrosis in mice.
d IL-33 polarized M2 macrophages to produce both IL-13
and TGF-b1 and induced the expansion of ILC2s to pro-
duce IL-13 in vitro and in vivo.
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Mice
C57BL/6 mice were purchased from Harlan Olac (Bicester, United
Kingdom). St22/2micewere on a C57BL/6 background.E1 Micewere housed
in specific pathogen-free conditions at Glasgow University, and procedures
were in accordance with the UK Home Office animal experimentation guide-
lines. Il33 transgenic micewere on a C57BL/6 backgroundE2 and housed in an
Association for Assessment andAccreditation of Laboratory Animal Care–ac-
credited facility (Beijing, China). The procedures were approved by the Insti-
tutional Animal Care and Use Committee of the Chinese Institute of
Laboratory Animal Science (GC-08-2018).
Bleomycin-induced fibrosis
C57BL/6 mice were lightly anaesthetized with isoflurane gas (4%), and
bleomycin sulfate (0.1 U per 25-g mouse in 30 mL of PBS; Sigma, St Louis,
Mo) or PBS was administered intranasally. BAL fluid, blood, and lungs were
harvested 7 or 14 days later and processed and analyzed, as described
previously.E3,E4 The time points selected in the experiments were determined
by our pilot experiments and by a consensus of the various time points used in
the literature describing mouse bleomycin-induced lung fibrosis. After
bleomycin instillation in mice, lung tissue displays typical acute inflammation
from days 1 to 5, and early expression of fibrotic markers and collagen
deposition can be seen from day 7 and is more pronounced by day 14. Thus
days 7 and 14 were used to investigate whether ST2 signals are involved in
early development and overall severity of lung fibrosis in St22/2 mice. Day
7 was also used to determine whether exogenous IL-33 instillation could
exacerbate bleomycin-induced fibrosis. The mice were inoculated
intranasally with a single dose (500 ng per mouse) of recombinant murine
mIL-33 (BioLegend, San Diego, Calif, or prepared as described previouslyE5)
on day 0 of bleomycin treatment and killed on day 7. Day 7 was also the end
point used for the macrophage depletion experiment to test whether this
procedure would abolish exogenous IL-33–exacerbated fibrotic effect seen
at day 7. Alveolar macrophage depletion was performed by means of
intranasal administration of clodronate (ClodLip BV) or control liposomes
(40 mL per mouse) at 24 and 72 hours before bleomycin administration, and
the mice were killed on day 7.E3,E6 Day 14 was selected to study the potential
therapeutic effect of neutralizing anti–IL-33 on the more severe established
fibrosis. The mice were treated intraperitoneally with neutralizing anti–IL-
33 antibodyE7 or control normal rabbit IgG (Sigma, 150 mg per mouse) on
the day of bleomycin administration and 5 and 10 days thereafter. The mice
were killed on day 14. Perfused lung tissue (100 mg) was dispersed in 1 mL
of ice-cold RIPA Lysis Buffer with a cocktail of protease inhibitors (Sigma)
for 45 minutes. Cell suspensions were centrifuged at 13,000 rpm in an
Eppendorf tube for 5 minutes, and the supernatant was collected for cytokine
and collagen assay.
Cell culture
Primary BMDMs were generated with macrophage colony-stimulating
factor (10 ng/mL; PeproTech, Rocky Hill, NJ), as described previously.E3
The subsequent cell preparations contained more than 95% F4/801
macrophages, as determined by using fluorescence-activated cell sorting.
The cells (0.5 3 106/mL) in culture medium were placed into 24-well plates
(Invitrogen) and cultured for 24 or 48 hours. Culture supernatants were stored
at2208C for cytokine analysis, and cells were harvested for mRNA extraction
for the qPCR assay.
Western blotting analysis
Tissue was lysed in RIPA buffer (Thermo Scientific, Uppsala, Sweden)
containing protease inhibitors (Roche, Mannheim, Germany). Protein
concentrations were estimated by using the BCA protein assay (Pierce,
Rockford, Ill). Proteins were then incubated at 708C for 10minutes in reducing
SDS sample buffer, and 30 mg of protein lysate per lane was run through
NuPAGE Novex 4-12% Bis-Tris Protein Gels (Life Technologies, Carlsbad,
Calif) and transferred to Hybond ECL membranes (GE Healthcare, Fairfield,
Conn). Membranes were blocked for 1 hour in 5% nonfat dried milk indouble-distilled PBS and incubated overnight with the appropriate primary
antibody at 48C.Membranes were then washed in double-distilled PBS/Tween
20 and incubated with the appropriate secondary antibody. Detection was
performed with ECLWestern Blotting Detection Reagents (GE Healthcare).
Antibodies against flIL-33 and mIL-33 were obtained from R&D Systems
(Minneapolis, Minn; AF3626, goat anti-mouse IL-33 polyclonal antibody);
cathepsin G, b-actin, and all secondary antibodies were obtained from Santa
Cruz Biotechnology (Dallas, Tex). The intensity of Western blot bands was
quantified bymeans of densitometry with ImageJ software (National Institutes
of Health, Bethesda, Md).
Determination of myeloperoxidase activity
Lung homogenates were prepared in 1 mL of RIPA buffer by using a tissue
homogenizer and myeloperoxidase assay performed as previously
described.E8 Results are expressed as relative units (OD, 492 nm) and were
corrected for the activity of other peroxidases, which were not inhibited by
3-amino-1,2,4-triazole.
Flow cytometry
Lungs were harvested on day 3 or 7 after bleomycin administration
and digested in 125 mg/mL Liberase TL and 100 mg/mL DNAse 1
(Roche Diagnostics) to characterize the infiltrating leukocytes. Dispersed
cells (13 106 cells per tube)were stainedwith 49-6-diamidino-2-phenylindole
dihydrochloride, UVE/DEAD fixable Aqua Dead cell stain (Life
Technologies), and fluorochrome-conjugated mAbs against F4/80-Pacific
blue (eBioscience, San Diego, Calif), cytokeratin 11–fluorescein
isothiocyanate (FITC; panepithelial cell marker; Abcam, Cambridge, United
Kingdom), ER-TF7–allophycocyanin (APC; panfibroblast marker, Santa
Cruz Biotechnology), CD3-PercP, CD11b-FITC or PercP, CD11c-APC,
CD49b–phycoerythrin (PE), CD206-APC, Ly6G-APC, Siglec-F–PE, MHC
class II–PercP, CD45-AF700, and isotype controls (all from BD Biosciences,
unless otherwise indicated). Leukocytes were stained with antibodies against
ST2–FITC (MD Biosciences), lineage markers (B220, FcεRI, CD11b, CD3ε,
and Siglec F) labeled with PE, CD45-AF700, and ICOS-PerCP/Cy5.5
(eBioscience) to characterize the infiltrating ILC2s. Intracellular IL-33 or
IL-13 was detected by staining with anti–IL-33–PE (R&D Systems) or anti–
IL-13–APC (eBioscience) after activation with phorbol 12-myristate 13-
acetate (50 ng/mL) and ionomycin (1 mg/mL) in the presence of BD
GolgiStop and cell permeabilization (BD Cytofix/Cytoperm, BD Biosci-
ences). Cells were analyzed with a Beckman Coulter CyAn ADP Analyzer
(Beckman Coulter, Fullerton, Calif). Gating strategy (Fig E4, A, and E5, A)
and analysis were performed with FlowJo software (TreeStar, Eugene, Ore).
ILC2 amplification and isolation and adoptive cell
transfer
For ILC2 amplification in vivo, mice were anesthetized with isoflurane and
treated with IL-33 (1 mg administered intranasally) daily for 5 days, as
described previously.E9 Lungs were harvested on day 6 and digested in 125
mg/mL Liberase TL and 100 mg/mL DNAse 1 (Roche Diagnostics). Nonad-
herent cells were stained for ST2, lineage markers, ICOS, CD45, and UVE/
DEAD fixable Aqua Dead cell stain (Life Technologies) as above and sorted
with a BD FACSAria. For cell transfer, 53 105 ILC2s in 40 mL of PBS were
inoculated intranasally 1 day after bleomycin challenge. Mice were culled on
day 7 after bleomycin instillation to assess lung inflammation and fibrosis.
Cytokine measurements
Concentrations of cytokines and chemokines in BAL fluid, cell cultures,
and whole-lung homogenates were determined by using Luminex (Luminex,
Biosource, Invitrogen) or ELISA (BD Biosciences), according to the
manufacturers’ instructions.
qPCR
RNA was purified from tissue samples by using the RNeasy Mini Kit
(Qiagen, Manchester, United Kingdom), according to the manufacturer’s
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1432.e2 LI ET ALinstructions. Reverse transcription of RNA into cDNA was carried out with
High-Capacity cDNAReverse TranscriptionKits (AppliedBiosystems, Foster
City, Calif). RT-PCR was performed with Fast SYBR Green master mix on a
Prism 7900HT (Applied Biosystems). The primers used were as follows: Il13
forward 59-GAATCC AGG GCTACA CAG AAC-39, reverse 59-AAC ATC
ACA CAA GAC CAG ACT C-39; Il33 forward 59-ACT ATG AGT CTC
CCT GTC CTG-39, reverse 59-ACG TCA CCC CTT TGA AGC-39; St2
forward 59-TCT GTG GAG TAC TTT GTT CAC C-39, reverse 59-TCT
GCTATT CTG GATACT GCT TTC-39; Tgfb1 forward 59-CCATGA GGA
GCA GGA AGG-39, reverse 59-ACA GCA AAG ATA ACA AAC TCC
AC-39; Arg1 forward 59-AGT GTT GAT GTC AGT GTG AGC-39, reverse
59-GAA TGG AAG AGT CAG TGT GGT-39; Nos2 forward 59-GCC TCG
CTC TGG AAA GA-39, reverse 59-TCC ATG CAG ACA ACC TT-39;
collagen 1 forward 59-CAT TGT GTA TGC AGT GAC TTC-39, reverse
59-CGC AAA GAG TCT ACA TGT CTA GGC-39; and collagen 3 forward
59-TCT CTA GAC TCATAG GAC TGA CC-39, reverse 59-TTC TTC TCA
CCC TTC TTC ATC C-39.
Collagen assay
The soluble collagen in lung tissues was quantified with the Sircol
Collagen Assay (Biocolor, Carrickfergus, United Kingdom), according to
the manufacturer’s instructions.
Histologic analysis
The larger left lung lobe was excised, fixed in 4% buffered formalin, and
embedded in paraffin. Sections (4 mm) were stained with hematoxylin and
eosin (Cellpath, Newtown, United Kingdom) or Gomori Rapid One-Step
Trichrome Stain (Sigma) for collagen. The pathology score (from 1-4) was
determined by using a method modified from a previous reportE10: 1, no
abnormal fibrosis; 2, occasional small interstitial fibrotic foci; 3, moderate
interalveolar septal thickening and fibrotic foci; and 4, continuous interalveo-
lar fibrosis.
Micro–computed tomographic scanning
Il33 transgenic mice, which overexpress the mature form of IL-33, were
kept in pathogen-free conditions for up to 6 months, and the development of
lung fibrosis was determined by using computed tomographic (CT) scans.
Scans were performed with a cone-beam micro-CT scanner (Inveon; Siemens
Healthcare, Munich, Germany), as previously described.E11 WT and Il33
transgenic mice were anesthetized and placed in the prone position on the
micro-CT bed without respiratory gating. The tube voltage was 70 kVp,
current was 400 mA, and exposure time was 800 ms. The scan field of view
was 72.44 mm 3 71.31 mm. Projection images were acquired with a
single tube/detector over a circular orbit of 3608 with a step angle of 18.
Reconstructions were performed by using a commercially available CTreconstruction program (COBRA Exxim, version 6.3), with a filtered
back-projection technique. A resolution of approximately 70.74 mm per pixel
was achieved.
Statistical analysis
Data were analyzed by using 1-way ANOVA, followed by Tukey or
Newman-Keuls post hoc analysis. One-way ANOVA was used to examine
mean differences between 2 ormore groups to compare everymeanwith every
other mean. Kinetic experiments (ie, cytokine expression over time or in vitro
data) were analyzed by using repeated-measures ANOVA. The analyses were
performed with GraphPad Prism 5.0 statistical software (GraphPad software,
San Diego, Calif). All results were presented as means and SEMs from 5 to 7
mice per group per experiment. Data are representative of at least 2 separated
experiments. A P value of less than .05 was considered to indicate statistical
significance.
FIG E1. Cytokine and chemokine concentrations quantified by means of ELISA in dispersed lung tissue
(in milligrams) supernatants of WT and St22/2 mice treated with PBS or bleomycin (BLM) at days 7 and 14
(A) and WT mice given bleomycin; treated with PBS, anti–IL-33, or control IgG; and killed on day 14 (B) are
shown. Vertical bars5means6 SEMs (n5 5-6mice per group per experiment) *P < .05 compared with PBS
control and #P < .05 compared with ST22/2 mice or IgG control values. Data are representative of 3
experiments.
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FIG E2. Bleomycin (BLM) induces IL-33 and ST2 production in fibrotic lung tissue. WT and St22/2mice were
given bleomycin, and lung tissues were analyzed on day 7. IL-33 concentration determined by means of
ELISA (A), St2 mRNA expression (B), myeloperoxidase (MPO) activity (C), and IL-33 isoforms, cathepsin
G, and b-actin detected by means of Western blotting (D) are shown. E, The intensity of Western blot bands
in Fig E2, D, was quantified by means of densitometry. Vertical bars 5 SEMs (n 5 6 mice per group per
experiment). *P < .05 compared with PBS values. Data are representative of 3 experiments.
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FIG E3. Depletion of alveolar macrophages reduces bleomycin (BLM)– and bleomycin plus IL-33–induced
lung inflammation. Mice were treated with PBS, clodronate in liposome (Clod), or liposomes alone (Lip)
1 day before administration of bleomycin or bleomycin plus IL-33. Lungs were harvested on day 7, and
lung tissue sections were stained with hematoxylin and eosin (original magnification 3200). Data are
representative of 3 experiments (n 5 5-6 mice per group per experiment).
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FIG E4. A, Flow cytometric gating strategy for analysis of macrophages in dispersed lung cell suspensions.
B-F,WT or St22/2mice were administered intranasally with PBS or bleomycin, and lung tissue harvested on
day 7 was dispersed. The percentage of macrophage subsets in the tissue was determined by using
flow cytometry. The percentage of macrophages (Fig E4, B), percentage of CD2061 (M2) macrophages
(Fig E4, C), percentage of IL-331M2 macrophages (Fig E4, D), isotype control for the anti–IL-33–PE staining
(Fig E4, E), and percentage and total number of MHC class II–positive macrophages (Fig E4, F) are shown.
Vertical bars 5 SEMs (n 5 5-6 mice per group per experiment). *P < .05 compared with control values.
Data are representative of 2 experiments. N.S., Not significant.
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FIG E5. Induction and function of ILC2s in lung fibrosis of mice. A,
Fluorescence-activated cell sorting gating strategy used for identification
of ILC2s in murine lung tissue. B, ILC2s from WT but not St22/2 mice
expressed ST2. C, Percentage of IL-131 ILC2s in lung tissue ofWTmice after
bleomycin (BLM) instillation. D and E, Adoptive transfer of ILC2s
contributes to lung inflammation in mice. WT mice were instilled with
PBS or bleomycin. Sorted ILC2s (5 3 105) were adoptively transferred
intranasally into mice 1 day after bleomycin instillation, and lung
inflammation was assessed on day 7. Fig E5, D, Hematoxylin and eosin
staining of lung tissues. Fig E5, E, Lung lavage fluid IL-13 and TGF-b1
concentrations quantified by means of ELISA. Vertical bars 5 SEMs
(n 5 5-6 mice per group per experiment). *P < .05 compared with PBS
control and #P < .05 compared with bleomycin control values. Data are
representative of 2 experiments.
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FIG E6. Schematic representation of the proposed mechanism of bleomycin (BLM)–induced IL-33 synthesis
and its contribution to lung fibrosis. Neomycin triggers release of flIL-33 from damaged airway epithelial
cells and recruitment of neutrophils. Neutrophil cathepsin G (CG) then processes flIL-33 to mIL-33.
mIL-33 stimulates alveolar macrophages and ILC2s to produce IL-13. mIL-33 and IL-13 then synergistically
polarize macrophages into the M2 macrophage phenotype, which produces more IL-33, IL-13, and TGF-b1
and in turn activates fibroblasts to proliferate and overproduce collagen. IL-33 also enhances macrophage
production of chemokines, which induce the infiltration of neutrophils and lymphocytes into the lung and
together might exacerbate lung inflammation and development of fibrosis. Mon, Monocytes; Neu,
neutrophils.
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FIG E7. Detection of IL-33–producing cell populations in bleomycin-induced fibrotic lung tissue. Mice were
given intranasal PBS or bleomycin (BLM) on day 0, and lung tissues were harvested on day 7. Tissues were
dispersed, and live single-cell preparations were stained with fluorescently labeled antibodies to CD45 to
categorize hematopoietic (A and B) and nonhematopoietic (C and D) cells. Staining for IL-33 and the
different cell linage markers are as described in the Methods section. Fluorescence-activated cell sorting
dot plots and histograms are presented. IL-331 cells were detected in macrophages (CD11b1F4/801;
Fig E7, A); conventional DCs (cDCs; CD11c1), CD11bdim, and resident/plasmacytoid DCs (Fig E7, B);
epithelial cells (cytokeratin 111; Fig E7, C); and fibroblasts (ER-TF71; Fig E7, D). Data are representative of
3 experiments (n 5 5-6 mice per group per experiment).
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FIG E8. Il33 transgenic mice have spontaneous lung fibrosis. WT and Il33 transgenic mice were kept in
pathogen-free conditions for up to 6 months. A, Lung tissues were stained for collagen deposition at 6
months. B, CT scan of mouse thorax was performed, and lung radiodensity scale (Hounsfield units [HU])
was calculated. C, Lung tissue collagen 1 and 3 mRNA expression was quantified by using qPCR. D, IL-33
concentration in mouse serum was quantified by means of ELISA at 2, 4, and 6 months of age. Vertical
bars 5 SEMs (n 5 10 mice per group per experiment). *P < .05 compared with WT control values.
Data are representative of 2 experiments.
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FIG E9. Detection of ST21 cell populations in bleomycin (BLM)–induced fibrotic lung tissue. Mice were
given intranasal PBS or bleomycin on day 0, and lung tissues were harvested on day 7. Tissues were
dispersed, and live single-cell preparations stained with fluorescently labeled antibodies to ST2 and
different cell linage markers, as described in the Methods section. Fluorescence-activated cell sorting dot
plots and histograms are presented. ST2 expression was detected on macrophages (CD11b1F4/801;
Fig E9, A), dendritic cells (CD11c1, conventional DCs [cDCs], CD11bdim and resident/plasmacytoid dendritic
cells [pDCs]; Fig E9, B), granulocytes (neutrophils [NOS] and eosinophils [EOS]), and lymphocytes
(Lymphs), natural killer (NK) cells, and natural killer T (NKT) cells (Fig E9, D). Data are representative of 2
experiments (n 5 5-6 mice per group per experiment).
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